Reduction of biologics in rheumatoid arthritis: a living systematic review and meta-analysis
PDF

Palavras-chave

Rheumatoid arthritis
Biologics
Dose reduction

Como Citar

VASCONCELOS, Leticia Breda e; GALVAO, Tais. Reduction of biologics in rheumatoid arthritis: a living systematic review and meta-analysis. Revista dos Trabalhos de Iniciação Científica da UNICAMP, Campinas, SP, n. 27, p. 1–1, 2019. DOI: 10.20396/revpibic2720192101. Disponível em: https://econtents.sbu.unicamp.br/eventos/index.php/pibic/article/view/2101. Acesso em: 19 mar. 2026.

Resumo

This living systematic review assesses the effectiveness and safety of reducing or spacing the dose of biological drugs in patients with rheumatoid arthritis at low disease activity, compared to standard dose treatment. Clinical outcomes data were collected and summarized in meta-analysis of standardized mean difference or relative risk. Most outcomes were non-significant.

PDF

Referências

Van Herwaarden, Noortje et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev, 2014;29(9):CD010455.

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-26.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Revista dos Trabalhos de Iniciação Científica da UNICAMP